NorthWest Biotherapeutics Inc (NWBO)

[Umibe5690]

It appears that Michael Platten and NWBO Mgmt/SAB have the same opinion. Based upon the info produced by the March, 2017 data collection, both parties appear to agree that efficacy of DC VAX L cannot be determined. That is the reason the trial has not been unblinded up to now and may not be for a while. Depends upon the spring 2018 refresh data.

Due to crossover confoundment and concerns about pseudo progression and the distinct possibility that PFS/OS endpoints may not have been achieved, focus is upon the long tail. In immunological approaches, long tail is the most important standard--at least that is what Linda Powers is telling us. Linda Liau appears to share similar views about the trial. Thus, it appears that all the foregoing experts are on the same page. The trial may still have a ways to go--2019 anyone?